FDA product approval
approved product. Vyleesi (bremelanotide); approval does not extend to research-labeled PT-141 products.
Melanocortin · compound · checked 2026-10-09
PT-141
PT-141 is bremelanotide. Vyleesi is an FDA-approved product for a specific premenopausal low-desire use. Research-market PT-141 vials and sprays are not Vyleesi. Listed seller masses here include 10 mg, 50 mg, and 100 mg labels.
Last checked Oct 9, 2026 by PepBear. Not medical advice.
- FDA product
- approved product
- Compounding
- not established
- Research
- product specific
- Sport
- unknown
What is PT-141?
The cited mechanism is melanocortin-receptor activity. Nasal research sprays and injectable research vials are different from the approved under-the-skin autoinjector. Large 50 mg and 100 mg listings are listing sizes, often sprays. They are not a copied label amount.
Bremelanotide is a melanocortin receptor agonist.
Regulatory status, dated 2026-10-09
Compounding
not established. Compounded products do not carry FDA product approval; legal eligibility is not established here.
Research
product specific. Premenopausal women with acquired, generalized hypoactive sexual desire disorder meeting the Vyleesi label.
Sport
unknown. Not individually verified; consult your sport authority.
What the cited papers actually measured
Approved-product evidence lives on the Vyleesi label and in the supporting low-desire trials (background including PMID 12904803 for bremelanotide’s melanocortin activity). Nausea, flushing, headache, and short blood-pressure rises appear in label materials. Those facts do not create a general wellness or tanning use. They do not validate research sprays.
We mark the cited papers as A. That is our label for how strong those papers are. It does not say the compound works.
How long it lasts, how you store it, listed sizes
The catalog does not record a single hour value. Not normalized across research products; see the approved-product pharmacokinetics.
Use the form you actually hold. A spray bottle and a freeze-dried vial do not share one chart assumption beyond the labeled mass you type.
U-100 math for listed PT-141 sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.
| Listed vial | 1 mL liquid | 2 mL liquid | 3 mL liquid |
|---|---|---|---|
| 10 mg | 100 | 50 | 33.3 |
| 50 mg | 500 | 250 | 166.7 |
| 100 mg | 1000 | 500 | 333.3 |
Risks and mix-ups already on the record
- Blood-pressure increases and nausea are label warnings.
- Uncontrolled hypertension or known cardiovascular disease are labeled contraindications.
- Delayed gastric emptying can affect absorption of oral medicines; the label advises avoiding oral naltrexone-containing products and reviewing medicines requiring threshold concentrations.
People using PepBear often log: Existing clinician-directed records, symptoms and dated health measurements. Record missing data; trends do not demonstrate causation.
Sources
- Primary evidence or regulator source · checked 2026-10-09
- DailyMed search for bremelanotide / Vyleesi · checked 2026-10-09
- Bremelanotide melanocortin paper (PubMed 12904803) · checked 2026-10-09
- FDA Vyleesi information · checked 2026-10-09
Questions people ask
Is research PT-141 the same as Vyleesi?
Vyleesi is a specific approved product and device. Research-market PT-141 listings do not inherit that approval.
Why do some listings say 100 mg?
That string appears on seller titles in the catalog file. It is a labeled mass for math. The page does not turn that mass into an amount to take.
Related cards
A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.